In the heart of the state that could decide the election, people are grappling with a crisis largely ignored by both Trump and Harris.
Health Care
The University of California has raked in a previously undisclosed $1.6 billion from Xtandi sales, and now doesn’t want the government lowering exorbitant drug costs.
The pharma giant previously received billions in federal funding and raked in huge profits, but owes nothing in 2023 income taxes thanks to legal loopholes and Trump-era tax cuts.
While industry leaders plead poverty to fight a proposed staffing standard, private equity owners are funneling cash into their affiliated real estate and management firms.
Why are generic drugmakers fighting a plan to let them make more medicines?
Right-wing federal appeal judges signal they support repeal of the no-cost preventive care mandate, all but guaranteeing a Supreme Court showdown.
As the first-ever Medicare drug-price negotiations take shape, Big Pharma-backed Democrats want to limit the number of costly medicines regulators can target.
Following a lobbying blitz, Congress might punt all efforts to stop shadowy pharmacy benefit managers from inflating drug prices and killing small pharmacies.
A bombshell report reveals that taxpayers spent billions developing medicines that drugmakers say shouldn’t face Medicare price negotiations.
The government is finally attempting to regulate overpriced drugs, but venture capital firms don’t want to lose their lucrative hold on life-saving pharmaceuticals.